Literature DB >> 18949495

Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients.

C Peña1, C Suarez, F Tubau, A Dominguez, M Sora, M Pujol, F Gudiol, J Ariza.   

Abstract

A cohort study was carried out on hospitalized adult non-critically ill patients (January 2003-December 2004) to identify factors associated with the acquisition of multidrug-resistant Pseudomonas aeruginosa (MDR-PA). A total of 246 non-critically patients were included, 162 (66%) who revealed MDR-PA in the first isolate and 84 (34%) who had carbapenem-resistant P. aeruginosa (CR-PA) isolates. Multivariate analysis identified nosocomial acquisition (odds ratio [OR] 2.7, 95% confidence interval [CI] 1.1-6.3), urinary catheter (OR 2.1, 95%CI 1.1-4.3), and the prior use of fluoroquinolones (OR 2.6, 95%CI 1.0-6.7) as independent risk factors associated with MDR-PA acquisition. Our results show that antibiotics, most notably, fluoroquinolones, may play a major role in the emergence of MDR-PA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949495     DOI: 10.1007/s10096-008-0645-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

1.  Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime.

Authors:  Samer A Alyaseen; Kerryl E Piper; Mark S Rouse; James M Steckelberg; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 4.  Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature.

Authors:  M E Falagas; P Kopterides
Journal:  J Hosp Infect       Date:  2006-07-05       Impact factor: 3.926

5.  Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa.

Authors:  Jane Kriengkauykiat; Edith Porter; Olga Lomovskaya; Annie Wong-Beringer
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Clinical prediction tool to identify patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk for multidrug resistance.

Authors:  Thomas P Lodise; Christopher D Miller; Jeffrey Graves; Jon P Furuno; Jessina C McGregor; Ben Lomaestro; Eileen Graffunder; Louise-Anne McNutt
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

7.  First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit.

Authors:  Saad Nseir; Christophe Di Pompeo; Stéphane Soubrier; Pierre Delour; Hélène Lenci; Micheline Roussel-Delvallez; Thierry Onimus; Fabienne Saulnier; Daniel Mathieu; Alain Durocher
Journal:  Crit Care Med       Date:  2005-02       Impact factor: 7.598

8.  Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.

Authors:  C Peña; A Guzmán; C Suarez; M A Dominguez; F Tubau; M Pujol; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

9.  Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.

Authors:  G Aubert; B Pozzetto; G Dorche
Journal:  J Antimicrob Chemother       Date:  1992-03       Impact factor: 5.790

10.  Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity.

Authors:  Elisabeth Paramythiotou; Jean-Christophe Lucet; Jean-François Timsit; Dominique Vanjak; Catherine Paugam-Burtz; Jean-Louis Trouillet; Stéphanie Belloc; Najiby Kassis; Andreas Karabinis; Antoine Andremont
Journal:  Clin Infect Dis       Date:  2004-02-17       Impact factor: 9.079

View more
  11 in total

1.  Enzymatic quorum quenching increases antibiotic susceptibility of multidrug resistant Pseudomonas aeruginosa.

Authors:  S Kiran; P Sharma; K Harjai; N Capalash
Journal:  Iran J Microbiol       Date:  2011-03

2.  Optimizing empiric antibiotic therapy in patients with severe β-lactam allergy.

Authors:  Lindsey P Koliscak; James W Johnson; James R Beardsley; David P Miller; John C Williamson; Vera P Luther; Christopher A Ohl
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 3.  A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Anne F Voor In 't Holt; Juliëtte A Severin; Emmanuel M E H Lesaffre; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

4.  A Pragmatic Machine Learning Model To Predict Carbapenem Resistance.

Authors:  Ryan J McGuire; Sean C Yu; Philip R O Payne; Albert M Lai; M Cristina Vazquez-Guillamet; Marin H Kollef; Andrew P Michelson
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

5.  Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration.

Authors:  Erlangga Yusuf; Bruno Van Herendael; Walter Verbrugghe; Margareta Ieven; Emiel Goovaerts; Kristof Bergs; Kristien Wouters; Philippe G Jorens; Herman Goossens
Journal:  Ann Intensive Care       Date:  2017-06-29       Impact factor: 6.925

Review 6.  How to manage Pseudomonas aeruginosa infections.

Authors:  Matteo Bassetti; Antonio Vena; Antony Croxatto; Elda Righi; Benoit Guery
Journal:  Drugs Context       Date:  2018-05-29

7.  [Nosocomial infections caused by multiresistant Pseudomonas aeruginosa (carbapenems included): predictive and prognostic factors. A prospective study (2016-2017))].

Authors:  A Hernández; G Yagüe; E García Vázquez; M Simón; L Moreno Parrado; M Canteras; J Gómez
Journal:  Rev Esp Quimioter       Date:  2018-03-21       Impact factor: 1.553

8.  Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection.

Authors:  Rachel Wheatley; Julio Diaz Caballero; Natalia Kapel; Fien H R de Winter; Pramod Jangir; Angus Quinn; Ester Del Barrio-Tofiño; Carla López-Causapé; Jessica Hedge; Gabriel Torrens; Thomas Van der Schalk; Basil Britto Xavier; Felipe Fernández-Cuenca; Angel Arenzana; Claudia Recanatini; Leen Timbermont; Frangiscos Sifakis; Alexey Ruzin; Omar Ali; Christine Lammens; Herman Goossens; Jan Kluytmans; Samir Kumar-Singh; Antonio Oliver; Surbhi Malhotra-Kumar; Craig MacLean
Journal:  Nat Commun       Date:  2021-04-28       Impact factor: 14.919

9.  Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis.

Authors:  Gowri Raman; Esther E Avendano; Jeffrey Chan; Sanjay Merchant; Laura Puzniak
Journal:  Antimicrob Resist Infect Control       Date:  2018-07-04       Impact factor: 4.887

10.  Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity.

Authors:  Milani Morteza; Salehi Roya; Hamishehkar Hamed; Zarebkohan Amir; Akbarzadeh Abolfazl
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.